IMVT Earnings & Financial Statements
Immunovant, Inc.
$27.95
+$0.05(+0.18%)
35
Overall
40
Value
36
Tech
31
Quality
Market Cap
$5.76B
Volume
40.29K
52W Range
$16.77 - $45.42
Target Price
$47.72
IMVT earnings and financial statements: Immunovant, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
IMVT Annual Financial Statements
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating income | -$532.90M | -$438.15M | -$282.71M | -$218.28M | -$156.03M |
| EBITDA | -$530.23M | -$437.17M | -$282.36M | -$217.21M | -$155.58M |
| Net income | -$505.61M | -$413.84M | -$259.34M | -$210.96M | -$156.73M |
| EPS (diluted) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | $957.01M | $776.22M | $666.37M | $405.84M | $515.56M |
| Total liabilities | $104.42M | $68.78M | $48.61M | $43.34M | $45.74M |
| Shareholders’ equity | $852.59M | $707.45M | $617.76M | $362.49M | $469.82M |
| Cash and equivalents | $902.11M | $713.97M | $635.37M | $376.53M | $493.82M |
| Long-term debt | - | - | - | $47.0K | $1.22M |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$407.31M | -$375.87M | -$214.23M | -$188.19M | -$106.11M |
| Capital expenditure | -$8.0K | -$759.0K | -$360.0K | -$197.0K | -$254.0K |
| Free cash flow | -$407.32M | -$376.63M | -$214.59M | -$188.39M | -$106.37M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMVT | $27.95 | +0.2% | 40.29K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |